Impact of obesity on PSA in prostate cancer screening;Impact de l'obésité sur le PSA lors du dépistage du cancer de la prostate

Progres en Urologie

Volumn 17, Issue 4, 2007, Pages 815-818

  Larré, Stéphane ^a,b   Azzouzi, Abdel Rahmène ^a,c   Cancel Tassin, Géraldine ^a   Cormier, Luc ^a,d   Villette, Jean Marie ^e   Hoffmann, Philippe ^f   Drelon, Isabelle ^a   Baschet, Françoise ^a   Mangin, Philippe ^a,c   Cussenot, Olivier ^a,g  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d CHU NANCY BRABOIS   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f CHR de Sarrebourg   (France)

^g HÔPITAL TENON   (France)

Author keywords

Body mass index; Obesity; Prostate specific antigen; Screening

Indexed keywords

EID: 34547189178     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1166-7087(07)92298-8     Document Type: Article

References (21)

1. CALLE E.E., RODRIGUEZ C., WALKER-THURMOND K., THUN M.J. : Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med., 2003 ; 348 : 1625-1638.
2. CHARLES M.A., BASDEVANT A., ESCHWEGE E. : Prevalence of obesity in adults in France: the situation in 2000 established from the OBEPI Study. Ann. Endocrinol., (Paris), 2002 ; 63 : 154-158.
3. CALLE E.E., RODRIGUEZ C., JACOBS E.J., ALMON M.L., CHAO A., MCCULLOUGH M.L., FEIGELSON H.S., THUN M.J. : The American Cancer Society Cancer Prevention Study II Nutrition Cohort : rationale, study design, and baseline characteristics. Cancer, 2002 ; 94 : 2490-2501.
4. ENGELAND A., TRETLI S., BJORGE T. : Height, body mass index, and prostate cancer : a follow-up of 950000 Norwegian men. Br. J. Cancer, 2003; 89: 1237-1242.
5. IRANI J., LEFEBVRE O., MURAT F., DAHMANIL., DORE B. : Obesity in relation to prostate cancer risk : comparison with a population having benign prostatic hyperplasia. BJU Int., 2003 ; 91 : 482-484.
6. RODRIGUEZ C., PATEL A.V., CALLE E.E., JACOBS E.J., CHAO A., THUN M.J. : Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol. Biomarkers Prev., 2001 ; 10 : 345-353.
7. GIOVANNUCCI E., RIMM E.B., LIU Y., LEITZMANN M., WU K., STAMPFER M.J., WILLETT W.C. : Body mass index and risk of prostate cancer in U.S. health professionals. J. Natl. Cancer Inst., 2003 ; 95 : 1240-1244.
8. PORTER M.P., STANFORD J.L. : Obesity and the risk of prostate cancer. Prostate, 2005; 62: 316-321.
9. FREEDLAND S.J., ARONSON W.J. : Obesity and prostate cancer. Urology, 2005 ; 65 : 433-439.
10. ABATE N., HAFFNER S.M., GARG A., PESHOCK R.M., GRUNDY S.M.: Sex steroid hormones, upper body obesity, and insulin resistance. J. Clin. Endocrinol. Metab., 2002 ; 87 : 4522-4527.
11. DESLYPERE J.P. : Obesity and cancer. Metabolism, 1995 ; 44 : 24-27.
12. KIM M.R., GUPTA M.K., TRAVERS S.H., ROGERS D.G., VAN LENTE F., FAIMAN C : Serum prostate specific antigen, sex hormone binding globulin and free androgen index as markers of pubertal development in boys. Clin. Endocrinol. (Oxf), 1999 ; 50 : 203-210.
13. BAILLARGEON J., POLLOCK B.H., KRISTAL A.R., BRADSHAW P., HERNANDEZ J., BASLER J., HIGGINS B., LYNCH S., ROZANSKI T., TROYER D., THOMPSON I. : The association of body mass index and prostate-specific antigen in a population-based study. Cancer, 2005 ; 103 : 1092-1095.
14. GRAY M.A., DELAHUNT B., FOWLES J.R., WEINSTEIN P., COOKES R.R., NACEY J.N. : Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives. Anticancer Res., 2004 ; 24 : 2069-2072.
15. KRISTAL A.R., CHI C., TANGEN C.M., GOODMAN P.J., ETZIONI R., THOMPSON I.M. : Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer, 2006 ; 106 : 320-328.
16. FOWKE J.H., SIGNORELLO L.B., CHANG S.S., MATTHEWS C.E., BUCHOWSKI M.S., COOKSON M.S., UKOLI F.M., BLOT W.J. : Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer, 2006; 107: 2361-2367.
17. THOMPSON I.M., LEACH R., TROYER D., POLLOCK B., NAYLOR S., HIGGINS B. : Relationship of body mass index and prostate specific antigen in a population-based study. Urol. Oncol., 2004 ; 22 : 127-131.
18. AZZOUZI A.R., LARRE S., CORMIER L., ROUPRET M., VALERI A., MANGIN P., BERTHON P., VILLETTE J.M., FIET J., CUSSENOT O. : Relevance of the prostate-specific antigen (PSA) nanotest compared to the classical PSA test in the organized mass screening of prostate cancer. BJU Int., 2007.
19. HAMMARSTEN J., HOGSTEDT B., HOLTHUIS N., MELLSTROM D. : Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis., 1998 ; 1 : 157-162.
20. DAHLE S.E., CHOKKALINGAM A.P., GAO Y.T., DENG J., STANCZYK F.Z., HSING A.W. : Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J. Urol., 2002 ; 168 : 599-604.
21. PARTIN A.W., CARTER H.B., CHAN D.W., EPSTEIN J.I., OESTERLING J.E., ROCK R.C., WEBER J.P., WALSH P.C. : Prostate specific antigen in the staging of localized prostate cancer : influence of tumor differentiation, tumor volume and benign hyperplasia. J. Urol., 1990 ; 143 : 747-752.